Probucol

When ATH:
C10AX02

Characteristic.

White or almost white, crystalline powder;.

Pharmacological action.
Hypolipidemic, hypocholesteremic, normalizing lipid metabolism, antiateroskleroticheskoe, antioksidantnoe.

Application.

Lipid metabolism, associated with increased cholesterol and / or LDL (atherosclerosis, hypercholesterolemia, hyperlipoproteinemia types IIa and IIb of Fridriksson) patients, whose diet, specific therapy (diabetes, gipotireoz) and exercise do not provide adequate lipid-lowering effect.

Contraindications.

Hypersensitivity, acute or recent myocardial infarction, ventricular arrhythmias, QT prolongation on an electrocardiogram by more than 15% the upper limit of normal, biliary cirrhosis.

Restrictions apply.

Bradycardia, kaliopenia, gipomagniemiya, arrhythmias or signs of recent or progressive myocardial damage, congestive heart failure, cholelithiasis, abnormal liver function.

Pregnancy and breast-feeding.

Contraindicated in pregnancy. Unknown, Whether probucol penetrates into breast milk during breastfeeding, however, it penetrates into the milk of animals. Use probucol during breast-feeding is not recommended because of possible serious adverse effects on the breast-fed baby.

Side effects.

From the nervous system and sensory organs: paraesthesia, dizziness, headache.

Cardio-vascular system and blood (hematopoiesis, hemostasis): increase QT interval on an electrocardiogram, associated with severe arrhythmias, ventricular arrhythmias (dizziness or fainting, palpitation, fast or irregular heartbeat), anemia, thrombocytopenia, eozinofilija.

From the digestive tract: diarrhea, gastralgia, flatulence, nausea, vomiting, anorexia.

Allergic reactions: angioedema.

Cooperation.

Simultaneous with the appointment of antiarrhythmic drugs, causing QT prolongation, such as: Amiodarone, bretiliya tosylate, disopyramide, lidokain, mexiletine, moracizin, prokaynamyd, propafenone, quinidine, sotalol, as well as tricyclic antidepressants and phenothiazine derivatives may lead to additive increase QT interval, which increases the risk of ventricular tachycardia. With simultaneous use of probucol, prolonging the QT interval, with beta-blockers (slow atrial conduction) and digoxin (inhibits atrioventricular conduction), able to cause bradycardia, may increase the risk of ventricular tachycardia.

Dosing and Administration.

Inside, by 0,5 g (2 once a day, while eating, preferably with foods, containing vegetable oil). After 1-1,5 months to reduce the dose 50%, and with more long-term employment — 80%. After 3-4 months of treatment make a break for 2-3 weeks.

Precautions.

It is necessary to take into account the expected effect and the potential risk in the following states: bradycardia, kaliopenia, gipomagniemiya (risk of ventricular paroxysmal tachycardia can be extended, tk. probucol increases the QT interval).

When arrhythmias, recent myocardial lesions or progressive condition may be exacerbated; the use of probucol is only possible under the periodic monitoring of ECG. Patients with a history of cardiac arrhythmias should periodically conduct an electrocardiogram. If any increase in the QT interval or cardiac arrhythmias probucol should be abolished.

Possible worsening of congestive heart failure or gallstones.

If abnormal liver function may increase the content of Probucol in blood.

It is recommended to determine the level of cholesterol and triglycerides in the plasma prior to treatment and every 3-4 months throughout therapy. If there is an increase in blood triglyceride concentration, it is recommended to adjust the diet food; If the increase in the concentration of triglycerides stored, probucol should be abolished.

Interrupt treatment should be supervised by a doctor, tk. blood lipids may then increase significantly.

Not recommended for children under 2 years (Cholesterol is essential for normal development of the child).

In appointing the probucol, the following changes in laboratory parameters: a slight increase in ALT levels, AST and ALP in serum, bilirubin, blood urea nitrogen, creatine, glucose and uric acid in the blood; a slight decrease in the number of eosinophils in the blood, levels of hemoglobin and hematocrit. The ECG is the case of QT interval prolongation.

Cautions.

Given the importance of dietary interventions in the treatment of lipid disorders, you must follow the prescribed diet. Probucol is designed to correct the patient's condition.

Probucol is recommended to be taken with food to improve absorption. When you miss a dose should be taken as soon as possible (if the close time for your next dose, take the missed dose should not be; do not double the dose).

If the 4 months of therapy no pronounced effect, therapy should be reviewed and, perhaps, canceled. The exception is tuberous xanthomas, as may be required until 1 year of treatment to reduce the size and / or number of xanthomas.

In severe and persistent disorders of lipid metabolism is a combination therapy with other lipid-lowering drugs (enterosorbents, lovastatin, nicotinic acid).

When a reception probucol recommended that the corresponding lipid-lowering diet and monitor the content of lipids in the blood plasma, until the patient's condition has stabilized, may occur because increasing the concentration of cholesterol in plasma at or above baseline.